Phospho-DPYSL2 (T509) Antibody

What is DPYSL2/CRMP2 and what role does phosphorylation at T509 play in its function?

DPYSL2 (Dihydropyrimidinase-related protein 2), also known as CRMP2 (Collapsin response mediator protein 2), is a cytosolic phosphoprotein abundantly expressed in the developing nervous system that plays crucial roles in neuronal development, polarity, axon growth and guidance, neuronal growth cone collapse, and cell migration. Phosphorylation at threonine 509 (T509) is part of a sequential phosphorylation cascade that regulates CRMP2's interaction with the cytoskeleton, particularly microtubules .

T509 phosphorylation occurs after priming phosphorylation by Cyclin-Dependent Kinase 5 (Cdk5) at S522, which enables glycogen synthase kinase 3β (GSK3β) to then phosphorylate T509, T514, and T518 . This phosphorylation sequence significantly reduces CRMP2's binding affinity for tubulin heterodimers, thereby regulating microtubule dynamics and neuronal processes .

How does phosphorylation status of CRMP2/DPYSL2 regulate its biological functions?

CRMP2's functions are tightly regulated by its phosphorylation status:

In its non-phosphorylated state, CRMP2 actively promotes microtubule assembly and stabilization, facilitating axonal growth and neuronal polarity establishment. Phosphorylation, particularly at T509 following the S522 priming event, removes CRMP2 from the microtubule network, inhibiting its growth-promoting functions . This dynamic regulation is critical during developmental processes such as semaphorin 3A-induced growth cone collapse, where phosphorylation of CRMP2 leads to cytoskeletal reorganization .

Why is monitoring DPYSL2 phosphorylation at T509 specifically important in neurological research?

Monitoring T509 phosphorylation is particularly important because:

• It serves as a critical indicator of GSK3β activity in neurons

• It reflects the activation status of upstream signaling pathways involving Cdk5

• Aberrant phosphorylation at this site is implicated in multiple neurological conditions including Alzheimer's disease, where hyperphosphorylated CRMP2 aggregates in amyloid plaques and neurofibrillary tangles prior to disease onset

• It provides insight into the regulation of axonal growth and neuronal regeneration capacity after injury

• Changes in T509 phosphorylation status correlate with neurodevelopmental disorders and intellectual disability

What are the optimal methods for detecting phosphorylated DPYSL2 at T509 in different sample types?

Different detection methods are appropriate depending on sample type and research question:

For optimal results when performing Western blot analysis, researchers should consider using positive controls such as heat-shocked HT-29 cells, which demonstrate increased phosphorylation at T509 . Validation of specificity can be performed using antigen-specific peptide competition assays to confirm signal specificity .

How should researchers design experiments to study the dynamics of DPYSL2 phosphorylation?

When designing experiments to study DPYSL2 phosphorylation dynamics:

• Include time course experiments to capture phosphorylation kinetics following stimulation

• Employ pharmacological inhibitors of Cdk5 (e.g., roscovitine) and GSK3β (e.g., SB216763) to confirm the signaling cascade

• Consider using both phosphorylation-specific antibodies and total DPYSL2 antibodies to calculate phosphorylation ratios

• Include appropriate controls:

  • Positive controls: tissues/cells with known high levels of T509 phosphorylation

  • Negative controls: samples treated with phosphatase inhibitors

  • Specificity controls: blocking peptides or phosphorylation-site mutants (T509A)

• For studying neuronal development or axon guidance, combine phosphorylation detection with functional readouts such as neurite length measurements or growth cone collapse assays

What are the critical considerations for sample preparation to preserve phosphorylation status?

To preserve the phosphorylation status of DPYSL2:

• Rapidly harvest and process samples to minimize post-collection dephosphorylation

• Include phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate) in all lysis buffers

• Maintain samples at 4°C during processing and avoid repeated freeze-thaw cycles

• For tissue sections, use phosphatase-preserving fixation protocols

• Consider using phosphorylation stabilizing fixatives like phospho-STOP™ supplemented buffers

• For long-term storage, maintain samples at -20°C or -80°C in buffers containing 50% glycerol and phosphatase inhibitors

How is DPYSL2 T509 phosphorylation implicated in Alzheimer's disease pathology?

In Alzheimer's disease (AD), CRMP2 phosphorylation at T509 shows significant dysregulation:

• Hyperphosphorylated CRMP2 (at S522, T509-T514-S518, T555) aggregates in amyloid plaques and neurofibrillary tangles prior to the onset of disease pathology

• Aβ accumulation increases CRMP2 phosphorylation by activating Cdk5, which phosphorylates S522, priming for subsequent GSK3β-mediated T509 phosphorylation

• This phosphorylation cascade removes CRMP2 from the microtubule network, dysregulating basic neuronal processes and contributing to synapse loss

• Genetically interfering with CRMP2 phosphorylation on S522 (which prevents subsequent T509 phosphorylation) has been shown to prevent Aβ-mediated impairment of long-term potentiation

• Compounds inhibiting Cdk5, GSK3β, and CRMP2 phosphorylation have demonstrated therapeutic potential in AD models, resulting in fewer aggregates, improved memory, and enhanced synaptic signaling

Researchers investigating AD mechanisms should consider phospho-T509 DPYSL2 as both a biomarker and potential therapeutic target.

What is known about DPYSL2 phosphorylation in neurodevelopmental disorders?

DPYSL2 phosphorylation dysregulation has been implicated in several neurodevelopmental disorders:

• Recent studies have identified de novo missense variants in DPYSL2 in individuals with autism spectrum disorder (ASD) and intellectual disability (ID)

• Two unrelated patients with ID and hypoplasia of the corpus callosum were found to have de novo missense variants (p.Ser14Arg or p.Arg565Cys) in DPYSL2

• Functional studies in zebrafish revealed that these mutations led to loss of DPYSL2 function and impaired interaction with tubulin

• DPYSL2-deficient mice exhibit ASD-like phenotypes, including:

  • Reduced spine density and dendritic branching in hippocampal and cortical neurons

  • Hyperactivity and social, cognitive, and affective behavioral impairments

  • Axonal pruning defects

  • Inadequate elimination of dendritic spines

  • Ultrasonic vocalization deficits in early postnatal period

These findings suggest that proper DPYSL2 phosphorylation regulation is crucial for normal neurodevelopment, and disruptions in this process may contribute to neurodevelopmental disorders.

How can phospho-DPYSL2 (T509) antibodies be used to investigate neuronal regeneration after injury?

Phospho-DPYSL2 (T509) antibodies serve as valuable tools for studying neuronal regeneration:

• After neuronal injury, phosphorylated CRMP2, along with myelin-associated inhibitors and semaphorin, congregate around scar tissue to suppress axonal growth and regeneration

• Studies using CRMP2 knock-in (CRMP2 KI) mice with phosphorylation-resistant mutations have shown enhanced axonal regeneration and functional recovery post-injury

• Researchers can use phospho-T509 antibodies to:

  • Monitor changes in phosphorylation status during the injury response

  • Assess the efficacy of interventions aimed at promoting axonal regeneration

  • Identify cells with regenerative capacity based on their CRMP2 phosphorylation profile

  • Evaluate the spatial and temporal dynamics of CRMP2 phosphorylation in injury models

• Combining phospho-T509 DPYSL2 detection with axonal growth markers provides insight into the relationship between phosphorylation status and regenerative capacity

How do different phosphorylation sites on DPYSL2 interact, and what experimental approaches can distinguish their individual contributions?

DPYSL2 contains multiple phosphorylation sites that function in a coordinated manner:

To distinguish individual contributions of these sites:

• Use site-specific phospho-antibodies in parallel experiments

• Employ phosphorylation-deficient mutants (e.g., T509A, S522A) in cellular models

• Design sequential immunoprecipitation experiments with different phospho-antibodies

• Use phosphatase treatment followed by site-specific re-phosphorylation with purified kinases

• Implement mass spectrometry techniques to quantify multi-site phosphorylation patterns

• Consider proximity ligation assays to detect specific phosphorylation combinations in situ

These approaches can reveal how T509 phosphorylation is influenced by and influences other modifications on DPYSL2.

What are the key considerations when interpreting contradictory results from phospho-DPYSL2 (T509) antibody experiments?

When faced with contradictory results:

• Antibody validation issues:

  • Confirm antibody specificity using blocking peptides and phosphorylation-site mutants

  • Verify consistency across antibody lots and suppliers

  • Use multiple detection methods to corroborate findings

• Technical variables:

  • Assess the impact of different sample preparation protocols on phosphorylation preservation

  • Consider tissue-specific differences in phosphatase activity

  • Evaluate the timing of sample collection relative to physiological/pathological events

• Biological complexity:

  • Account for developmental or cell-type specific differences in phosphorylation regulation

  • Consider compensatory mechanisms in genetic models

  • Evaluate the ratio of phosphorylated to total protein rather than absolute levels

• Signaling context:

  • Examine upstream regulators (Cdk5, GSK3β) and their activation status

  • Investigate cross-talk with other post-translational modifications

  • Consider whether results reflect acute vs. chronic changes in phosphorylation

How can researchers effectively combine phospho-DPYSL2 (T509) antibody-based approaches with other methods to gain comprehensive insights into neuronal development and pathology?

For comprehensive understanding, researchers should:

• Integrate multiple analytical approaches:

  • Combine antibody-based detection with mass spectrometry for unbiased phosphoproteomic analysis

  • Correlate phosphorylation status with functional readouts (e.g., microtubule binding assays)

  • Use live-cell imaging with phospho-sensors to track dynamic changes

• Implement multi-omics strategies:

  • Relate phosphorylation changes to transcriptomic alterations

  • Explore connections between DPYSL2 phosphorylation and the broader phosphoproteome

  • Investigate the impact on interactome using proximity labeling approaches

• Utilize advanced microscopy:

  • Apply super-resolution techniques to visualize subcellular distribution of phosphorylated DPYSL2

  • Employ FRET-based sensors to monitor real-time phosphorylation

  • Use correlative light and electron microscopy to relate phosphorylation to ultrastructural features

• Leverage genetic models:

  • Compare findings across multiple model systems (rodents, zebrafish, human neurons)

  • Use CRISPR-based approaches to generate phosphorylation site mutations

  • Employ conditional/inducible systems to control the timing of phosphorylation changes

These integrated approaches will provide a more complete understanding of how T509 phosphorylation contributes to DPYSL2 function in health and disease.

How might extracellular CRMP2 and its phosphorylation status influence neurological disease progression?

Recent discoveries suggest novel roles for extracellular CRMP2:

• An extracellular pool of CRMP2 has been identified that may act as an agonist for NMDA receptors

• In Alzheimer's disease, the trans-synaptic transfer of pathological Tau and other prion-like proteins contributes to disease propagation

• There is emerging speculation that phosphorylated CRMP2 might participate in prion-like propagation of pathology through trans-synaptic transfer

Future research directions should:

• Investigate whether phospho-T509 DPYSL2 is found in extracellular vesicles

• Determine if phosphorylation status affects the propensity for extracellular release

• Explore whether phosphorylated CRMP2 can be transmitted between neurons

• Assess whether antibodies against phospho-T509 DPYSL2 might have therapeutic potential by targeting extracellular forms

What novel therapeutic approaches targeting DPYSL2 phosphorylation are being explored?

Emerging therapeutic strategies include:

• Development of small molecule inhibitors that specifically prevent T509 phosphorylation without interfering with other GSK3β substrates

• Design of peptide mimetics that bind to CRMP2 and shield the T509 site from phosphorylation

• Gene therapy approaches using phosphorylation-resistant CRMP2 variants to promote axonal regeneration after injury

• Targeted protein degradation approaches (PROTACs) that selectively eliminate phosphorylated CRMP2

• Identification of naturally occurring compounds that modulate the Cdk5-GSK3β-CRMP2 phosphorylation cascade